WO2005123123A3 - Reprogrammation therapeutique, cellules souches hybrides et maturation - Google Patents

Reprogrammation therapeutique, cellules souches hybrides et maturation Download PDF

Info

Publication number
WO2005123123A3
WO2005123123A3 PCT/US2005/005052 US2005005052W WO2005123123A3 WO 2005123123 A3 WO2005123123 A3 WO 2005123123A3 US 2005005052 W US2005005052 W US 2005005052W WO 2005123123 A3 WO2005123123 A3 WO 2005123123A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
stem cells
maturation
therapeutically
therapeutic reprogramming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/005052
Other languages
English (en)
Other versions
WO2005123123A2 (fr
Inventor
Chauncey B Sayre
Francisco J Silva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PrimeGen Biotech LLC
Original Assignee
PrimeGen Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/864,788 external-priority patent/US20050090004A1/en
Priority to JP2007527196A priority Critical patent/JP2008501795A/ja
Priority to AU2005253923A priority patent/AU2005253923A1/en
Priority to RU2006147263/14A priority patent/RU2006147263A/ru
Priority to BRPI0511889-1A priority patent/BRPI0511889A/pt
Priority to CA002567692A priority patent/CA2567692A1/fr
Application filed by PrimeGen Biotech LLC filed Critical PrimeGen Biotech LLC
Priority to EP05723204A priority patent/EP1758989A2/fr
Publication of WO2005123123A2 publication Critical patent/WO2005123123A2/fr
Publication of WO2005123123A3 publication Critical patent/WO2005123123A3/fr
Priority to IL179927A priority patent/IL179927A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/061—Sperm cells, spermatogonia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des cellules programmées par voie thérapeutique et des procédés de production desdites cellules. Les cellules programmées par voie thérapeutique sont des cellules souches qui ont été portées à maturation de façon à représenter un état plus différencié ou un état moins différencié après mise en contact avec des facteurs de stimulation. Lesdites cellules programmées par voie thérapeutique sont destinées à être utilisées en thérapie régénérative cellulaire et présentent un potentiel de différenciation en lignées cellulaires plus engagées. L'invention concerne en outre des cellules souches hybrides pour la reprogrammation thérapeutique et la thérapie régénérative cellulaire.
PCT/US2005/005052 2004-06-08 2005-02-16 Reprogrammation therapeutique, cellules souches hybrides et maturation Ceased WO2005123123A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP05723204A EP1758989A2 (fr) 2004-06-08 2005-02-16 Reprogrammation therapeutique, cellules souches hybrides et maturation
AU2005253923A AU2005253923A1 (en) 2004-06-08 2005-02-16 Therapeutic reprogramming, hybrid stem cells and maturation
RU2006147263/14A RU2006147263A (ru) 2004-06-08 2005-02-16 Терапевтическое перепрограммирование, гибридные стволовые клетки и созревание
BRPI0511889-1A BRPI0511889A (pt) 2004-06-08 2005-02-16 reprogramação terapêutica, células-tronco hìbridas e maturação
CA002567692A CA2567692A1 (fr) 2004-06-08 2005-02-16 Reprogrammation therapeutique, cellules souches hybrides et maturation
JP2007527196A JP2008501795A (ja) 2004-06-08 2005-02-16 ハイブリッド幹細胞の治療的再プログラミングおよび成熟
IL179927A IL179927A0 (en) 2004-06-08 2006-12-07 Therapeutic reprogramming, hybrid stem cells and maturation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/864,788 US20050090004A1 (en) 2003-01-16 2004-06-08 Stem cell maturation for all tissue lines
US10/864,788 2004-06-08
US58814604P 2004-07-15 2004-07-15
US60/588,146 2004-07-15

Publications (2)

Publication Number Publication Date
WO2005123123A2 WO2005123123A2 (fr) 2005-12-29
WO2005123123A3 true WO2005123123A3 (fr) 2006-03-02

Family

ID=35355246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/005052 Ceased WO2005123123A2 (fr) 2004-06-08 2005-02-16 Reprogrammation therapeutique, cellules souches hybrides et maturation

Country Status (7)

Country Link
EP (1) EP1758989A2 (fr)
JP (1) JP2008501795A (fr)
AU (1) AU2005253923A1 (fr)
BR (1) BRPI0511889A (fr)
CA (1) CA2567692A1 (fr)
RU (1) RU2006147263A (fr)
WO (1) WO2005123123A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090252711A1 (en) * 2006-05-11 2009-10-08 Andrew Craig Boquest Stem Cells And Methods Of Making And Using Stem Cells
CA2679185A1 (fr) 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited Derives d'acetamide 2,2,2-tri-substitue en tant qu'activateurs de la glucokinase, leur procede de preparation et leur application pharmaceutique
CA2688136A1 (fr) 2007-06-08 2008-12-11 Advinus Therapeutics Private Limited Nouveaux derives de pyrrole-2-carboxamide en tant qu'activateurs de la glucokinase, leur procede d'obtention et leur application pharmaceutique
EP2090649A1 (fr) 2008-02-13 2009-08-19 Fondazione Telethon Procédé de reprogrammation de cellules différentiées
EP2402327B1 (fr) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Composés d'acétamide en tant qu'activateurs de la glucokinase, leur procédé et applications médicales
EP2796873A1 (fr) * 2013-04-25 2014-10-29 QGel SA Procédé pour un test de criblage de médicaments à base de cellules et son utilisation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006701A1 (fr) * 1998-07-31 2000-02-10 Genzyme Corporation Amelioration du fonctionnement cardiaque par transplantation de cellules souches mesenchymateuses
WO2002051980A2 (fr) * 2000-12-12 2002-07-04 Nucleus Remodeling, Inc. Cellules souches adultes multipotentes derivees in vitro et leurs utilisations
WO2003027278A1 (fr) * 2001-09-21 2003-04-03 Reprocell Inc. Cellules souches multifonctionnelles adaptees et utilisation de ces dernieres
WO2003062384A2 (fr) * 2002-01-16 2003-07-31 Chauncey Sayre Maturation de cellules souches pour tous les types de tissus
WO2003102126A1 (fr) * 2002-05-31 2003-12-11 Apollo Life Sciences Pty Ltd Methode de therapie cellulaire faisant appel a des hybrides cellulaires fusionnes
WO2004046312A2 (fr) * 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Illinois Methodes de developpement in vitro de cellules souches hematopoietiques

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006701A1 (fr) * 1998-07-31 2000-02-10 Genzyme Corporation Amelioration du fonctionnement cardiaque par transplantation de cellules souches mesenchymateuses
WO2002051980A2 (fr) * 2000-12-12 2002-07-04 Nucleus Remodeling, Inc. Cellules souches adultes multipotentes derivees in vitro et leurs utilisations
WO2003027278A1 (fr) * 2001-09-21 2003-04-03 Reprocell Inc. Cellules souches multifonctionnelles adaptees et utilisation de ces dernieres
EP1437404A1 (fr) * 2001-09-21 2004-07-14 ReproCELL Inc. Cellules souches multifonctionnelles adaptees et utilisation de ces dernieres
WO2003062384A2 (fr) * 2002-01-16 2003-07-31 Chauncey Sayre Maturation de cellules souches pour tous les types de tissus
WO2003102126A1 (fr) * 2002-05-31 2003-12-11 Apollo Life Sciences Pty Ltd Methode de therapie cellulaire faisant appel a des hybrides cellulaires fusionnes
WO2004046312A2 (fr) * 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Illinois Methodes de developpement in vitro de cellules souches hematopoietiques

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DONOVAN P J & DE MIGUEL M P: "Turning germ cells into stem cells.", CURRENT OPINION IN GENETICS & DEVELOPMENT, vol. 13, no. 5, October 2003 (2003-10-01), pages 463 - 471, XP002355791, ISSN: 0959-437X *
MOENS A ET AL: "Differential ability of male and female rabbit fetal germ cell nuclei to be reprogrammed by nuclear transfer.", DIFFERENTIATION, vol. 60, no. 5, September 1996 (1996-09-01), pages 339 - 345, XP002355344, ISSN: 0301-4681 *
TADA M ET AL: "Embryonic germ cells induce epigenetic reprogramming of somatic nuclear in hybrid cells", EMBO JOURNAL, vol. 16, no. 21, 1997, pages 6510 - 6520, XP002960229, ISSN: 0261-4189 *
TADA M ET AL: "Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells", CURRENT BIOLOGY, vol. 11, no. 19, 2 October 2001 (2001-10-02), pages 1553 - 1558, XP002960228, ISSN: 0960-9822 *
YAMAZAKI Y ET AL: "Adult mice cloned from migrating primordial germ cells.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 32, 9 August 2005 (2005-08-09), pages 11361 - 11366, XP002355792, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2005253923A1 (en) 2005-12-29
WO2005123123A2 (fr) 2005-12-29
RU2006147263A (ru) 2008-07-20
CA2567692A1 (fr) 2005-12-29
EP1758989A2 (fr) 2007-03-07
BRPI0511889A (pt) 2008-01-15
JP2008501795A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
EP1719196A4 (fr) Materiaux d'electrodes actifs de batteries secondaires et procedes de fabrication associes
WO2008079997A3 (fr) Mécanisme et procédé d'angiogenèse et dispositif implantable
WO2007149861A3 (fr) Réparation de tissu mou et régénération à l'aide des produits de cellules souches
GB2431582B (en) Dendritic cell vaccines made from embryonic stem cells for treating cancer
EP1812556A4 (fr) Progeniteurs neuronaux obtenus par culture de cellules souches embryonnaires humaines sans cellules nourricieres
WO2007127927A3 (fr) Différentiation de cellules souches embryonnaires humaines
WO2005047524A3 (fr) Compositions et procedes pour induire la differenciation cellulaire
IL184043A0 (en) A method for enhancing cardiomyocyte differentiation, cell cultures for use therein and isolated cardiomyocytes produced thereby
WO2007056994A3 (fr) Procede de production de lignees cellulaires humaines permanentes
IL178232A0 (en) Methods for growing pluripotent stem cells
WO2006074075A3 (fr) Cellules souches derivees du tissu adipeux pour la regeneration tissulaire et la cicatrisation de plaies
PT2266544T (pt) Método para introdução de substâncias terapêuticas em células
WO2005005601A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer
WO2006074308A3 (fr) Regeneration des ilots pancreatiques par traitement des cellules souches du liquide amniotique
EP2361303B8 (fr) Cellule souche de type stromale multipotente isolée de glomérules humains adultes (hgl-msc), son procédé de préparation et ses utilisations en médecine régénérative du rein
PL1838355T3 (pl) Ulepszone sposoby wygaszania dla procesu inaktywacji czerwonych krwinek
WO2007026255A3 (fr) Cellules dedifferenciees et procedes permettant de realiser et d'utiliser des cellules dedifferenciees
AU2003272877A1 (en) Electrode for fuel cell, fuel cell including the electrode and process for producing the same
WO2005041944A3 (fr) Procedes et compositions favorisant la regeneration des axones et le remplacement therapeutique de cellules
WO2012100083A3 (fr) Cellules neuronales induites humaines
AU2003221108A1 (en) Positive electrode material for lithium secondary cell and secondary cell using the same, and method for producing positive electrode material for lithium secondary cell
WO2003070905A3 (fr) Procedes d'electroporation pour introduire des agents bioactifs dans des cellules
WO2005123123A3 (fr) Reprogrammation therapeutique, cellules souches hybrides et maturation
WO2009134962A3 (fr) Peptide liant claudin-4, compositions et procédés d'utilisation
WO2006084229A3 (fr) Utilisation de substance nucleaire aux fins de reprogrammation therapeutique de cellules differenciees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2567692

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005723204

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3609/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 179927

Country of ref document: IL

Ref document number: 2007527196

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 447.06

Country of ref document: BZ

Ref document number: 2005253923

Country of ref document: AU

Ref document number: 200580018783.5

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006147263

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005253923

Country of ref document: AU

Date of ref document: 20050216

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005253923

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005723204

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0511889

Country of ref document: BR